In the first six months the revenue totaled DKK 31.1 billion compared to DKK 29.8 billion in the same period last year, while EBITDA was DKK 875 million compared to DKK 950 million in H1 2024. The decline in EBITDA is driven by an impairment due to the reconstruction process in Enorm Biofactory, as well as challenging grain markets in H1.
An important milestone in the first half of 2025 was the launch of the three-year transformation programme, ReGen.
“We saw stable development across several core business segments in the first half of the year, which supported operating profit from core activities. However, the results delivered still fall short of our ambitions and potential. Our key priority is to extract more value through focus and improved competitiveness. Therefore, we have launched ReGen to futureproof DLG Group by increasing efficiency, strengthening competitiveness and accelerating value creation,” says Group CEO Peter Giørtz-Carlsen and continues:
“2025 is a transition year where we are cleaning up and investing in the transformation to improve our core business. We have identified our full potential, our plan is clear, and we are confident that current actions will lay the foundation for stronger and more stable results in the future. A transformation of this scale takes time and demands consistent effort. We remain focused on delivering on our targets and executing with discipline to secure long-term value creation for our owners.”
